Incyte Corporation
INCYLast close · Oct 16, 2026113.07−0.20 (−0.18%)
Market cap$22.9B
Between Jul 31, 2026 and Oct 1, 2026, Incyte (INCY) insiders filed 40 Form 4 transactions: 11 sales worth $10.0M in total and no open-market purchase; 11 of the sales were under 10b5-1 plans set in advance. The largest seller was Cagnoni Pablo J, $1.9M. 29 other filings were grants, exercises or gifts, which say nothing about buying or selling.
40
0
11
33
Form 4 transactions
| Date | Insider | Title | Code | Plan | Shares | Price | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Heeson Lee | EVP, Head of Incyte Intl | F | 463 | 117.14 | $54,235.8 | |
| 2026-09-30 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Director, 10% Owner | A | 322 | 0.00 | $0 | |
| 2026-09-30 | BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN | Director, 10% Owner | A | 322 | 0.00 | $0 | |
| 2026-09-30 | Clancy Paul J | Director | A | 203 | 121.35 | $24,634.1 | |
| 2026-09-30 | HARRIGAN EDMUND | Director | A | 206 | 121.35 | $24,998.1 | |
| 2026-09-22 | Gardner David H | EVP, Chief Strategy Officer | F | 920 | 126.93 | $116,775.6 | |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 4,551 | 61.18 | $278,430.2 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 6,477 | 64.25 | $416,147.3 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 9,233 | 71.93 | $664,129.7 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | S | 10b5-1 | 9,233 | 120.50 | $1.1M |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | S | 10b5-1 | 13,985 | 120.49 | $1.7M |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 2,957 | 0.00 | $0 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 4,551 | 0.00 | $0 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 6,477 | 0.00 | $0 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 9,233 | 0.00 | $0 |
| 2026-09-15 | CAGNONI PABLO J | President, Global Head of R&D | M | 10b5-1 | 2,957 | 61.76 | $182,624.3 |
| 2026-08-25 | Basi Ramitpal K | EVP, Human Resources | F | 504 | 129.72 | $65,378.9 | |
| 2026-08-19 | CAGNONI PABLO J | President, Global Head of R&D | S | 10b5-1 | 10,801 | 125.56 | $1.4M |
| 2026-08-12 | CAGNONI PABLO J | President, Global Head of R&D | S | 10b5-1 | 10,803 | 120.04 | $1.3M |
| 2026-08-05 | CAGNONI PABLO J | President, Global Head of R&D | S | 10b5-1 | 10,640 | 122.69 | $1.3M |
| 2026-08-05 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,207 | 106.47 | $234,979.3 |
| 2026-08-05 | Mayes Patrick A | EVP & Chief Scientific Officer | S | 10b5-1 | 2,207 | 123.99 | $273,645.9 |
| 2026-08-05 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,207 | 0.00 | $0 |
| 2026-07-31 | CAGNONI PABLO J | President, Global Head of R&D | S | 10b5-1 | 15,888 | 119.70 | $1.9M |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | S | 10b5-1 | 326 | 121.69 | $39,670.9 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 3,023 | 0.00 | $0 |
| 2026-08-03 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 6,055 | 105.43 | $638,378.7 |
| 2026-08-03 | Mayes Patrick A | EVP & Chief Scientific Officer | S | 10b5-1 | 6,055 | 120.43 | $729,203.7 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,918 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,284 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,709 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 3,148 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,072 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 9,459 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,623 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,864 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 1,643 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | S | 10b5-1 | 2,293 | 119.41 | $273,807.1 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | M | 10b5-1 | 2,623 | 0.00 | $0 |
| 2026-07-31 | Mayes Patrick A | EVP & Chief Scientific Officer | S | 10b5-1 | 85 | 122.19 | $10,386.2 |
Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Method notes in where the numbers come from.